Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
Phase 1/2 Terminated
3 enrolled 8 charts
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
34 enrolled 15 charts
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
AMEERA-1
Phase 1/2 Terminated
136 enrolled 60 charts
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1/2 Terminated
175 enrolled
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
Phase 1/2 Terminated
9 enrolled 21 charts
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Phase 1/2 Terminated
10 enrolled 11 charts
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Phase 1/2 Terminated
9 enrolled 7 charts
ELONA
Phase 1/2 Terminated
4 enrolled
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
40 enrolled 20 charts
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Phase 1/2 Terminated
6 enrolled
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
70 enrolled 24 charts
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1/2 Terminated
15 enrolled
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Phase 1/2 Terminated
46 enrolled
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
Phase 1/2 Terminated
5 enrolled 6 charts
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Phase 1/2 Terminated
7 enrolled
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1/2 Terminated
3 enrolled 6 charts
CamBMT1
Phase 1/2 Terminated
26 enrolled
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Phase 1/2 Terminated
79 enrolled 22 charts
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Phase 1/2 Terminated
99 enrolled 21 charts
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1/2 Terminated
6 enrolled
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Phase 1/2 Terminated
223 enrolled 50 charts
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Phase 1/2 Terminated
12 enrolled 16 charts
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase 1/2 Terminated
27 enrolled 12 charts
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Phase 1/2 Terminated
6 enrolled 7 charts
SSTR2+
Phase 1/2 Terminated
9 enrolled 4 charts
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Phase 1/2 Terminated
30 enrolled 14 charts
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Phase 1/2 Terminated
2 enrolled 9 charts
A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Phase 1/2 Terminated
1 enrolled
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Phase 1/2 Terminated
12 enrolled 13 charts
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Phase 1/2 Terminated
152 enrolled 42 charts
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
Phase 1/2 Terminated
18 enrolled
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Phase 1/2 Terminated
31 enrolled
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
Phase 1/2 Terminated
34 enrolled
EXTENT
Phase 1/2 Terminated
4 enrolled 6 charts
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Phase 1/2 Terminated
12 enrolled
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Phase 1/2 Terminated
25 enrolled 9 charts
Vaccine Treatment for Advanced Breast Cancer
Phase 1/2 Terminated
3 enrolled
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
Phase 1/2 Terminated
32 enrolled 10 charts
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Phase 1/2 Terminated
16 enrolled 21 charts
ABI-008 Trial in Patients With Metastatic Breast Cancer
Phase 1/2 Terminated
85 enrolled
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
Phase 1/2 Terminated
12 enrolled 6 charts
PembroMab
Phase 1/2 Terminated
16 enrolled 6 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Phase 1/2 Terminated
3 enrolled 14 charts
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Phase 1/2 Terminated
69 enrolled 34 charts
Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
Phase 1/2 Terminated
2 enrolled 7 charts
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
31 enrolled 8 charts
TAKTIC
Phase 1/2 Terminated
68 enrolled